DMD

Chr XXLRX-linked

dystrophin

Also known as: BMD, CMD3B, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268

This gene spans a genomic range of greater than 2 Mb and encodes a large protein containing an N-terminal actin-binding domain and multiple spectrin repeats. The encoded protein forms a component of the dystrophin-glycoprotein complex (DGC), which bridges the inner cytoskeleton and the extracellular matrix. Deletions, duplications, and point mutations at this gene locus may cause Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or cardiomyopathy. Alternative promoter usage and alternative splicing result in numerous distinct transcript variants and protein isoforms for this gene. [provided by RefSeq, Dec 2016]

OMIMResearchGenerating clinical summary…
LOFmechanismXLR/X-linkedLOEUF 0.154 OMIM phenotypes
Clinical SummaryDMD
🧬
Gene-Disease Validity (ClinGen)
progressive muscular dystrophy · XLDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.15LOEUF
pLI 1.000
Z-score 10.69
OE 0.10 (0.070.15)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
-2.43Z-score
OE missense 1.19 (1.141.24)
1568 obs / 1319.4 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.10 (0.070.15)
00.351.4
Missense OE?1.19 (1.141.24)
00.61.4
Synonymous OE?1.20
01.21.6
LoF obs/exp: 17 / 165.4Missense obs/exp: 1568 / 1319.4Syn Z: -3.44
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveDMD-related Duchenne muscular dystrophyLOFXLR
Mechanism Note (expert annotation)
LOF

Dystrophin. Frameshift/nonsense mutations cause complete LOF (Duchenne). In-frame deletions preserving partial function cause milder Becker phenotype. This is a classic LOF gene; the Badonyi GOF prediction is incorrect.1

This gene — mechanism propensity

DN
0.7228th %ile
GOF
0.80top 10%
LOF
0.4726th %ile

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function, gain-of-function and dominant-negative). The Badonyi & Marsh model scores gain-of-function highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports loss-of-function (haploinsufficiency). Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFLOEUF 0.15 · ClinGen HI: Sufficient evidence for dosage pathogenicity
GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 2352866

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

DMD · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Duchenne Muscular Dystrophy

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

ACTIVE NOT RECRUITING
NCT04281485Phase PHASE3PfizerStarted 2020-11-05
PF-06939926PlaceboPlacebo
Duchenne Muscular Dystrophy

Long Term Follow-up for RGX-202

ENROLLING BY INVITATION
NCT06491927REGENXBIO Inc.Started 2024-05-08
No Intervention
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

RECRUITING
NCT07429240Phase PHASE1, PHASE2Precision BioSciences, Inc.Started 2026-04-24
PBGENE-DMD (IV)
Duchenne Muscular Dystrophy (DMD)

A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.

ACTIVE NOT RECRUITING
NCT06392724Phase EARLY_PHASE1Peking Union Medical College HospitalStarted 2024-07-05
GEN6050X intravenous injection
Impacted Third Molar ToothPain, Acute

Variability in Analgesic Response to Ibuprofen

RECRUITING
NCT06539741University of PennsylvaniaStarted 2025-01-03
Duchenne Muscular Dystrophy

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

ACTIVE NOT RECRUITING
NCT03368742Phase PHASE1, PHASE2Solid Biosciences Inc.Started 2017-12-06
SGT-001
FSHD

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

RECRUITING
NCT04635891University of Kansas Medical CenterStarted 2020-12-15
OsteoporosisSarcopeniaObesity

Skeletal Maturation and Endocrine Health in Young Adults

ENROLLING BY INVITATION
NCT06509776Holbaek SygehusStarted 2024-11-11
Duchenne Muscular Dystrophy

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

ACTIVE NOT RECRUITING
NCT06100887Phase PHASE2Edgewise Therapeutics, Inc.Started 2024-03-22
Sevasemten Dose 1Sevasemten Dose 2Sevasemten Dose 3
Duchenne Muscular Dystrophy

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

ENROLLING BY INVITATION
NCT06270719Sarepta Therapeutics, Inc.Started 2024-02-07
Delandistrogene MoxeparvovecStandard of Care
Duchenne Muscular Dystrophy

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)

ACTIVE NOT RECRUITING
NCT06114056Phase PHASE1West China HospitalStarted 2024-01-31
JWK007 Single intravenous infusion administration
Duchene Muscular Dystrophy

A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

RECRUITING
NCT07127978ITF Therapeutics LLCStarted 2025-10-23